Results 41 to 50 of about 279,790 (190)

T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients [PDF]

, 2016
textabstractAutologous T cells were genetically modified to express a chimeric antigen receptor (CAR) directed toward carboxy-anhydrase-IX (CAIX) and used to treat patients with CAIX-positive metastatic renal cell carcinoma.
Cor H. J. Lamers, Reno Debets, Sabine C. L. van Steenbergen, Stefan Sleijfer, Yarne Klaver   +4 more
core   +4 more sources

Nanotechnology Promotes Genetic and Functional Modifications of Therapeutic T Cells Against Cancer

Advanced Science, 2020
Growing experience with engineered chimeric antigen receptor (CAR)‐T cells has revealed some of the challenges associated with developing patient‐specific therapy.
Ahmed M. E. Abdalla, Lin Xiao, Yu Miao, Lixia Huang, Gendeal M. Fadlallah, Mario Gauthier, Chenxi Ouyang, Guang Yang   +7 more
doaj   +1 more source

Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice

eJHaem, 2022
In recent years, we have seen rapid expansion of chimeric antigen receptor T‐cell (CAR‐T) therapies in multiple malignancies. CAR‐T therapy has profoundly altered the treatment landscape of non‐Hodgkin lymphoma, B‐cell acute lymphoblastic leukemia, and ...
Salyka Sengsayadeth, Bipin N. Savani, Olalekan Oluwole, Bhagirathbhai Dholaria   +3 more
doaj   +1 more source

Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia

Journal for ImmunoTherapy of Cancer, 2023
The treatment of B cell malignancies has dramatically changed with the introduction of immunotherapy, especially chimeric antigen receptor T (CAR-T) cell therapy. However, only limited efficacy is observed in acute myeloid leukaemia (AML).
Ting Yang, Jingjing Wen, Yanxin Chen, Jiajie Yang, Chunye Dai, Shenjie Yu, Wenting Zhong, Lilin Liu, Chengguanng He, Wenmin Zhang, Lingfeng Liu, Jianda Hu   +11 more
doaj   +1 more source

Young T Cells Age During a Redirected Anti-Tumor Attack: Chimeric Antigen Receptor-Provided Dual Costimulation is Half the Battle [PDF]

, 2013
Adoptive therapy with chimeric antigen receptor (CAR)-redirected T cells showed spectacular efficacy in the treatment of leukemia in recent early phase trials.
Andreas A. Hombach, Hinrich Abken
core   +2 more sources

Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. [PDF]

, 2017
T-cells play a critical role in tumor immunity. Indeed, the presence of tumor-infiltrating lymphocytes is a predictor of favorable patient prognosis for many indications and is a requirement for responsiveness to immune checkpoint blockade therapy ...
Ackerman, Ahmed, Ansell, Araki, Ascierto, Beatty, Beatty, Blagih, Borkner, Brahmer, Brandacher, Brentjens, Brentjens, Bridgeman, Brocker, Brudno, Buck, Buckanovich, Burnette, Butler, Butler, Carpenito, Caruana, Caruso, Chang, Chang, Chen, Chen, Chen, Cherkassky, Chmielewski, Church, Colegio, Cordoba, Cretenet, Crompton, Cui, Curiel, Curran, Deaglio, Demaria, Doedens, Facciabene, Fesnak, Finney, Fischer, Fousek, Fox, Frauwirth, Frauwirth, Fridman, Fuertes, Gabrilovich, Gajewski, Gajewski, Galon, Gargett, Gattinoni, Gattinoni, Gattinoni, Geiger, Geissmann, Gill, Gobert, Govers, Gracias, Grada, Gross, Gross, Gubin, Gubser, Guest, Guppy, Hall, Hamanishi, Han, Harlin, Herrera, Hinrichs, Hinrichs, Ho, Hodi, Hombach, Hombach, Hombach, Hsu, Huang, Hudecek, Hwang, Iida, Ino, Irving, Italiani, James, Jass, Jensen, Jensen, Ji, Jones, Joyce, June, Justus, Kahlon, Kawalekar, Kerkar, Kershaw, Kershaw, Khalil, Khalil, Klebanoff, Klebanoff, Klebanoff, Klug, Lamers, Lanitis, Lanitis, Larkin, Le, Le, Lee, Li, Lipson, Liu, Liu, Lochner, Long, Louis, Lugli, Lunt, MacIver, Mahoney, Martinez-Forero, Marvel, Maude, Maus, Maus, Mellor, Menetrier-Caux, Mikucki, Miller, Mittal, Moon, Morgan, Morgan, Morsut, Motz, Motz, Motzer, Muniappan, Munn, Munn, Munn, Murdoch, Nghiem, Niederman, Noman, Okamoto, Otsuji, O’Sullivan, O’Sullivan, Palazón, Palmer, Pameijer, Pandiyan, Paolino, Pardoll, Parry, Patsoukis, Pearce, Pegram, Peng, Peng, Pipkin, Pluta, Porter, Powles, Prosser, Rabinovich, Rathmell, Restifo, Rizvi, Rodriguez, Rodriguez, Rosenberg, Rosenberg, Roybal, Salerno, Sallusto, Santoro, Savoldo, Scharping, Schmid, Schwartz, Semenza, Sharpe, Sikalidis, Sinclair, Singh, Sivan, Smith, Snyder, Sommermeyer, Spranger, Spranger, Spranger, Srivastava, Stromnes, Suarez, Sukumar, Sukumar, Tamada, Tan, Taylor, Terakura, Topalian, Topalian, Topalian, Torikai, Tran, Tumeh, Turatti, Urbanska, Uyttenhove, van der Merwe, van der Waart, van der Windt, van der Windt, van der Windt, van Rooij, Vander Heiden, Vuillefroy de Silly, Vuillefroy de Silly, Vétizou, Waickman, Wang, Wang, Wang, Wang, Wang, Warburg, Wherry, Willemsen, Wing, Wofford, Wu, Xu, Yang, Yang, Yaqoob, Zhang, Zhang, Zhang, Zheng   +252 more
core   +1 more source

Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies

Chinese Medical Journal, 2023
. Cellular therapies have revolutionized the treatment of hematological malignancies since their conception and rapid development. Chimeric antigen receptor (CAR)-T cell therapy is the most widely applied cellular therapy.
Zhihuan Yang, Ying Wang, Peifang Wei
doaj   +1 more source

Nephrotoxicity in CAR-T Cell Therapy

Transplantation and Cellular Therapy
Chimeric antigen receptor (CAR)-T cell therapy is a novel therapy for the treatment of different hematologic malignancies. Besides its efficiency, CAR-T cell therapy is associated with significant toxicity, primarily manifested as cytokine release syndrome (CRS) and neurotoxicity.
Karol Sadowski, Weronika Ploch, Alicja Downar, Wiktoria Giza, Dorota Szcześ, Wioletta Olejarz, Wiesław W. Jędrzejczak, Jolanta Małyszko, Grzegorz Basak   +8 more
openaire   +2 more sources

The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies

ImmunoMedicine, 2022
Chimeric antigen receptors (CAR) T‐cell therapy is one of the most effective treatments in curing hematologic malignancies. Besides the four CD19 CAR T‐cells therapy recently approved by the US Food and Drug Administration (FDA), CD20 CAR T‐cell therapy ...
Elaine Tan Su Yin, Yong Xian Hu, He Huang   +2 more
doaj   +1 more source

Oncologic Emergencies: Immune-Based Cancer Therapies and Complications [PDF]

, 2020
Cancer therapies have undergone several recent advancements. Current cancer treatments include immune-based therapies comprised of checkpoint inhibitors, and adoptive immunotherapy; each treatment has the potential for complications that differ from ...
Brém, Elizabeth, Koyfman, Alex, Long, Brit Jeffrey   +2 more
core